<p>Increased Expression of TAP Is Predictive of Poor Prognosis in Patients with Non-Small Cell Lung Cancer</p>

Abstract

Background: The most common cancer among humans is lung cancer. Non-small cell lung cancer (NSCLC) comprises the majority of these cases. In the development and progression of cancers across the spectrum, tumor abnormal protein (TAP) plays crucial roles. Additionally, in the advancement of the bladder and colorectal cancers, the involvement of glycoproteins like TAP is present. However, it is worth noting that current literature has yet to clarify the clinical significance of the TAP in NSCLC. Methods: In the present study, to evaluate the relative level of TAP, we utilized a TAP detection agent in 154 cases of NSCLC and normal patients who underwent surgical resection anytime from March 2013 to January 2019 at the People's Hospital of Chizhou. Results: Our results demonstrated that in NSCLC patients, the expression level of TAP was significantly higher than in normal patients. Moreover, after surgery, TAP expression was significantly downregulated in NSCLC patients. TAP expression is associated with an array of factors, which include the patient's sex, history of smoking use, tumor size, pTNM, distant cancer, metastasis of lymph nodes, invasive and aggressive indicator pleural invasion, and differentiation degree of NSCLC. Additionally, TAP has no association with the patient's age, history of drinking, location of the tumor, hypertension, and diabetes. In NSCLC patients, a poor overall survival rate within 5 years is significantly correlated with the increased TAP expression. For NSCLC patients, an independent prognostic factor is the TAP, which is confirmed using the multivariate survival analysis. Conclusion: In the malignant progression of NSCLC, our results demonstrate how the promoting role of the upregulated TAP expression takes place. Hence, a therapeutic aim for NSCLC and a potential biomarker for NSCLC progress is a TAP.

Early Study of Tumor Abnormal Protein in Gastric Adenocarcinoma

“…Many recent studies have demonstrated the sensitivity and specificity of TAP for the early screening, diagnosis, and prognosis of tumors. [8][9][10][11] In this study, we collected peripheral blood samples from 95 patients with gastric adenocarcinoma and 34 nontumor patients and evaluated the influence of TAP expression on screening diagnosis based on these samples. The positive rate of TAP in patients with gastric adenocarcinoma (68.4%) was significantly higher than that in nontumor patients (23.5%), indicating that TAP is more sensitive to gastric cancer; in other words, TAP can be used to monitor gastric adenocarcinoma.…”

High Expression of Tumor Abnormal Protein Preoperatively Predicts Poor Prognosis of Patients With Esophageal Squamous Cell Carcinoma

“…In addition to ESCC, TAP was also obviously expressed in stomach cancer, colorectal cancer, thyroid cancer, and bladder cancer, as well as lung cancer ( 9 – 12 , 21 , 22 ). The results of the study generally reviewed the role played by TAP in the development as well as the progression of tumor.…”

RSPH14 regulates the proliferation, cell cycle progression, and apoptosis of non‐small cell lung cancer cells

“…The 5-year survival rates for patients with advanced and metastatic NSCLC are 24 and 4%, respectively [3]. Previous studies have reported a series of regulators involved in controlling NSCLC metastasis, including TWIST1 [4], PTCH1 [5] and TGF-β-induced long non-coding RNAs (lncRNAs) [6].…”

“…In addition, the 5‐year survival rate of NSCLC remains low compared with other common cancers, such as colorectal, breast, and prostate cancers [ 2 ]. The 5‐year survival rates for patients with advanced and metastatic NSCLC are 24 and 4%, respectively [ 3 ]. Previous studies have reported a series of regulators involved in controlling NSCLC metastasis, including TWIST1 [ 4 ], PTCH1 [ 5 ], and TGF‐β‐induced long noncoding RNAs (lncRNAs) [ 6 ].…”